Colleen Sjogren
Förmögenhet: 559 440 $ per 2026-08-31
Förmögenhet: 559 440 $ per 2026-08-31
Ms. Colleen Sjogren is a Chief Commercial Officer at Nuvation Bio, Inc. Ms. Sjogren was previously employed as a Senior Vice President-Sales by Madrigal Pharmaceuticals, Inc., a VP-US Sales, Sales Training & Meeting Planning by Mirati Therapeutics, Inc., and a Vice President-National Cell Therapy & Sales by Kite Pharma, Inc. She received her undergraduate degree from Bryant University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-02-27 | 84 000 ( 0,02 % ) | 559 440 $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| NUVATION BIO INC. | Företagsledare/Principal | 2024-03-28 |
| Företag | Position | Slut |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Försäljning & Marknadsföring | 2023-12-01 |
| MIRATI THERAPEUTICS | Försäljning & Marknadsföring | 2022-09-01 |
| KITE PHARMA INC | Försäljning & Marknadsföring | 2021-04-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cancer therapies | Health Technology |
Bryant University
Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kite Pharma, Inc.
Kite Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company which engages in the development of novel cancer immunotherapeutic products | Health Technology |
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Nuvation Bio, Inc.
Nuvation Bio, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops oncology related novel therapeutic candidates | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån